Point Therapeutics

NCT07426484

CollaboratorPhase 4Recruiting202680 people23 Feb 2026clinicaltrials.gov

NCT07397338

CollaboratorPhase 1/2Recruiting2026370 people9 Feb 2026clinicaltrials.gov

A Study of PHST001 in Advanced Solid Tumors

Phase 1Recruiting2025426 people21 Feb 2025clinicaltrials.gov

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Phase 2Completed2024447 people8 Oct 2024clinicaltrials.gov

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1Recruiting2024238 people19 Sept 2024clinicaltrials.gov

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Phase 2Completed2024469 people29 Jul 2024clinicaltrials.gov

NCT05828303

Phase 1Withdrawn20240 people25 Apr 2023clinicaltrials.gov

NCT05794581

Phase 1Completed202332 people3 Apr 2023clinicaltrials.gov

NCT05112536

Phase 2Completed202224 people9 Nov 2021clinicaltrials.gov

NCT04902885

CollaboratorPhase 3Completed202195 people26 May 2021clinicaltrials.gov

NCT04887831

Phase 2Terminated202192 people14 May 2021clinicaltrials.gov

NCT04786964

Phase 3Terminated202125 people8 Mar 2021clinicaltrials.gov

NCT03877562

Phase 1Completed201996 people15 Mar 2019clinicaltrials.gov

NCT03508635

Phase 1Completed2014130 people26 Apr 2018clinicaltrials.gov

NCT03457597

Phase 1Completed201827 people7 Mar 2018clinicaltrials.gov

NCT03335956

Phase 1Completed201748 people8 Nov 2017clinicaltrials.gov

NCT03315338

Phase 1Completed2017143 people20 Oct 2017clinicaltrials.gov

NCT00083252

Phase 2Completed18 May 2004clinicaltrials.gov